Literature DB >> 26695091

Long-term Outcomes of Patients With Giant Intracranial Arteriovenous Malformations.

Wuyang Yang1, Zhikui Wei, Joanna Y Wang, Alice L Hung, Justin M Caplan, Maria Braileanu, Geoffrey P Colby, Alexander L Coon, Rafael J Tamargo, Judy Huang.   

Abstract

BACKGROUND: Giant intracranial arteriovenous malformations (AVMs) are rare cerebrovascular lesions that pose management challenges.
OBJECTIVE: To further clarify outcomes in patients with giant cerebral AVMs managed with conservative or interventional therapies.
METHODS: We performed a retrospective review of all patients diagnosed with AVMs evaluated at our institution from 1990 to 2013. Patients with a single intracranial AVM >6 cm were included. Patients were divided into 2 groups: conservative management or intervention (microsurgery, radiosurgery, or embolization). Functional outcome was assessed with the modified Rankin Scale (mRS) and compared between the 2 groups.
RESULTS: A total of 55 patients with giant AVMs were included, and 35 patients (63.6%) had clinical follow-up with a mean of 11.8 years. Spetzler-Martin grades were as follows: grade III, n = 2 (3.6%); grade IV, n = 15 (27.3%); and grade V, n = 38 (69.1%). Twenty-four patients (43.6%) were conservatively managed. The patients in the conservatively managed group had larger AVMs (P < .05) with more frequent involvement of the temporal lobe (P = .02). Five patients (26.3%) in the conservatively managed group and 5 (31.3%) in the intervention group experienced hemorrhage during follow-up, translating to an annualized risk of 2.7% and 4.1%, respectively. No significant difference in risk of first subsequent hemorrhage was observed (P = .78). Despite comparable mRS scores at presentation, we observed a trend toward better outcomes (mRS < 2) in patients undergoing conservative management (P = .06) compared with the intervention group at last follow-up.
CONCLUSION: This study suggests that interventions for giant AVMs should be considered cautiously because hemorrhagic risk is similar regardless of management strategy and functional outcome is likely to be same or better in the conservatively managed population. ABBREVIATIONS: AVM, arteriovenous malformationmRS, modified Rankin Scale.

Entities:  

Mesh:

Year:  2016        PMID: 26695091     DOI: 10.1227/NEU.0000000000001189

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Assessment of Explicitly Stated Interval Change on Noncontrast Head CT Radiology Reports.

Authors:  M Braileanu; K Crawford; S R Key; M E Mullins
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-30       Impact factor: 3.825

2.  Extensive Cerebral Arteriovenous Malformation-Associated Intraventricular Hemorrhage.

Authors:  Amine Awad; Kow Essuman; Robert W Regenhardt; Thabele M Leslie-Mazwi; Aman B Patel; Christopher J Stapleton
Journal:  Neurohospitalist       Date:  2021-09-27

3.  Contemporary management of brain arteriovenous malformations in mainland China: a web-based nationwide questionnaire survey.

Authors:  Yu Chen; Xiangyu Meng; Li Ma; Yang Zhao; Ye Gu; Hengwei Jin; Dezhi Gao; Youxiang Li; Shibin Sun; Ali Liu; Yuanli Zhao; Xiaolin Chen; Shuo Wang
Journal:  Chin Neurosurg J       Date:  2020-09-01

4.  Comparison of Endovascular Embolization Plus Simultaneous Microsurgical Resection vs. Primary Microsurgical Resection for High-Grade Brain Arteriovenous Malformations.

Authors:  Mingze Wang; Fa Lin; Hancheng Qiu; Yong Cao; Shuo Wang; Jizong Zhao
Journal:  Front Neurol       Date:  2021-12-24       Impact factor: 4.003

Review 5.  Expert Consensus on the Management of Brain Arteriovenous Malformations.

Authors:  Yoko Kato; Van He Dong; Feres Chaddad; Katsumi Takizawa; Tsuyoshi Izumo; Hitoshi Fukuda; Takayuki Hara; Kenichiro Kikuta; Yasunobu Nakai; Toshiki Endo; Hiroki Kurita; Bin Xu; Vladimír Beneš; Raftopoulos Christian; Giacomo Pavesi; Mojgan Hodaie; Rajan Kumar Sharma; Harshal Agarwal; Krishna Mohan; Boon Seng Liew
Journal:  Asian J Neurosurg       Date:  2019-11-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.